Kashiv BioSciences has secured INR 648 crore in financing from the Union Bank of India to expand its biopharmaceutical manufacturing infrastructure in Pipan, near Ahmedabad, Gujarat as part of a major investment in advanced biologics production.
Kashiv BioSciences, a wholly owned subsidiary of Kashiv BioSciences LLC (USA), has multiple commercial and advanced clinical-stage assets and is among a limited number of firms that both manufacture and receive marketing authorisations for several biosimilars.
The funds will support the development of a state-of-the-art single-use commercial manufacturing facility that, once fully operational, is expected to have a capacity of up to 50,000 litres, making it one of the largest biologics plants of its kind in India.
The facility will be equipped with cutting-edge technologies aimed at producing high-quality biologics and specialty pharmaceuticals. The expansion forms a central part of Kashiv’s strategy to strengthen its global footprint in biomanufacturing and position India as a major hub for advanced pharmaceutical production. The new infrastructure is expected to enhance technical capabilities, improve competitiveness in international markets including the United States, Canada and Europe, and create long-term, high-value employment across scientific, technical and operational roles.
The financing from Union Bank of India aligns with broader policy support through the Gujarat State Biotechnology Mission (GSBTM) and the state’s biotechnology policy, which offers incentives for advanced biotech investment. The project aims to accelerate innovation, expand access to high-quality biologics and bolster India’s role in global healthcare supply chains.
Also Read